Arrowhead Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Millions USD. Fiscal year is Oct - Sep.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep '25 Sep 30, 2025	Sep '24 Sep 30, 2024	Sep '23 Sep 30, 2023	Sep '22 Sep 30, 2022	Sep '21 Sep 30, 2021
Cash & Equivalents	224.65	99.19	102.99	100.71	184.43
Short-Term Investments	692.82	578.28	292.74	268.39	183.36
Cash & Short-Term Investments	917.47	677.46	395.73	369.1	367.79
Cash Growth	35.43%	71.19%	7.22%	0.36%	16.58%
Receivables	6.82	-	-	1.41	10.26
Prepaid Expenses	10.93	9.54	8.81	7.29	4.36
Restricted Cash	1.9	3.5	7.9	7.3	-
Other Current Assets	13.52	4.97	4.03	20.2	2.19
Total Current Assets	950.64	695.47	416.47	405.3	384.6
Property, Plant & Equipment	426.41	431.29	335.56	168.59	66.02
Long-Term Investments	-	-	-	105.87	245.6
Other Intangible Assets	6.86	8.56	10.26	11.96	13.66
Other Long-Term Assets	1.39	4.48	3.26	0.22	0.27
Total Assets	1,385	1,140	765.55	691.94	710.15
Accounts Payable	17.67	11.39	35.87	2.87	9.46
Accrued Expenses	96.24	80.8	43.68	59.11	23.77
Short-Term Debt	10.3	-	-	-	-
Current Portion of Long-Term Debt	40	-	-	-	-
Current Portion of Leases	7.29	6.34	10.56	2.78	2.25
Current Income Taxes Payable	20.8	-	-	-	-
Current Unearned Revenue	2.4	-	0.87	74.1	111.06
Other Current Liabilities	0.79	4.64	14.48	-	-
Total Current Liabilities	195.49	103.17	105.46	138.85	146.54
Long-Term Debt	582.28	734.54	268.33	-	-
Long-Term Leases	104.11	111.03	104.61	78.8	23.3
Long-Term Unearned Revenue	-	-	-	55.95	131.5
Total Liabilities	881.88	948.74	478.39	273.6	301.33
Common Stock	0.23	0.22	0.2	0.2	0.2
Additional Paid-In Capital	2,140	1,806	1,300	1,219	1,053
Retained Earnings	-1,627	-1,626	-1,026	-820.76	-644.69
Treasury Stock	-53.19	-	-	-	-
Comprehensive Income & Other	6.44	4.75	-3.22	-0.14	-0.07
Total Common Equity	466.05	185.44	271.34	398.52	408.82
Minority Interest	37.36	5.62	15.82	19.82	-
Shareholders' Equity	503.42	191.06	287.16	418.34	408.82
Total Liabilities & Equity	1,385	1,140	765.55	691.94	710.15
Total Debt	743.98	851.91	383.5	81.58	25.55
Net Cash (Debt)	173.49	-174.45	12.23	287.52	342.24
Net Cash Growth	-	-	-95.75%	-15.99%	16.27%
Net Cash Per Share	1.30	-1.46	0.11	2.73	3.30
Filing Date Shares Outstanding	135.81	124.43	107.43	106.01	104.53
Total Common Shares Outstanding	135.7	124.38	107.31	105.96	104.33
Working Capital	755.15	592.3	311.02	266.45	238.06
Book Value Per Share	3.43	1.49	2.53	3.76	3.92
Tangible Book Value	459.19	176.88	261.08	386.56	395.16
Tangible Book Value Per Share	3.38	1.42	2.43	3.65	3.79
Land	3	3	3	3	-
Buildings	251.32	75.99	-	-	-
Machinery	88	71.93	58.75	40.47	29.67
Construction In Progress	15.94	188.73	166.66	56.37	0.35
Leasehold Improvements	104.43	104.41	103.81	42.02	41.52

Source: S&P Global Market Intelligence. Standard template. Financial Sources.